BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 30117669)

  • 1. Detecting tumour response and predicting resectability after neoadjuvant therapy for borderline resectable and locally advanced pancreatic cancer.
    Barreto SG; Loveday B; Windsor JA; Pandanaboyana S
    ANZ J Surg; 2019 May; 89(5):481-487. PubMed ID: 30117669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How to approach pancreatic cancer after neoadjuvant treatment: assessment of resectability using multidetector CT and tumor markers.
    Jeon SK; Lee JM; Lee ES; Yu MH; Joo I; Yoon JH; Jang JY; Lee KB; Lee SH
    Eur Radiol; 2022 Jan; 32(1):56-66. PubMed ID: 34170366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection.
    Marchegiani G; Todaro V; Boninsegna E; Negrelli R; Sureka B; Bonamini D; Salvia R; Manfredi R; Pozzi Mucelli R; Bassi C
    Eur Radiol; 2018 Oct; 28(10):4265-4273. PubMed ID: 29679211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pretherapeutic evaluation of patients with upper gastrointestinal tract cancer using endoscopic and laparoscopic ultrasonography.
    Mortensen MB
    Dan Med J; 2012 Dec; 59(12):B4568. PubMed ID: 23290296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CT prediction of resectability and prognosis in patients with pancreatic ductal adenocarcinoma after neoadjuvant treatment using image findings and texture analysis.
    Kim BR; Kim JH; Ahn SJ; Joo I; Choi SY; Park SJ; Han JK
    Eur Radiol; 2019 Jan; 29(1):362-372. PubMed ID: 29931561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Added value of intra-operative ultrasound to determine the resectability of locally advanced pancreatic cancer following FOLFIRINOX chemotherapy (IMAGE): a prospective multicenter study.
    van Veldhuisen E; Walma MS; van Rijssen LB; Busch OR; Bruijnen RCG; van Delden OM; Mohammad NH; de Hingh IH; Yo LS; van Laarhoven HW; van Leeuwen MS; Nio CY; van Santvoort HC; de Vries J; Wessels FJ; Wilmink JW; Molenaar IQ; Besselink MG; van Lienden KP;
    HPB (Oxford); 2019 Oct; 21(10):1385-1392. PubMed ID: 31010633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endoscopic ultrasonography complements computed tomography in predicting portal or superior mesenteric vein resection in patients with borderline resectable pancreatic carcinoma.
    Glazer ES; Rashid OM; Klapman JB; Harris CL; Hodul PJ; Pimiento JM; Malafa MP
    Pancreatology; 2017; 17(1):130-134. PubMed ID: 28043760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma.
    Wagner M; Antunes C; Pietrasz D; Cassinotto C; Zappa M; Sa Cunha A; Lucidarme O; Bachet JB
    Eur Radiol; 2017 Jul; 27(7):3104-3116. PubMed ID: 27896469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: An intention to treat analysis.
    Barenboim A; Lahat G; Geva R; Nachmany I; Nakache R; Goykhman Y; Brazowski E; Rosen G; Isakov O; Wolf I; Klausner JM; Lubezky N
    Eur J Surg Oncol; 2018 Oct; 44(10):1619-1623. PubMed ID: 30146251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Utility of EUS-FNA to Determine Surgical Candidacy in Patients with Pancreatic Cancer after Neoadjuvant Therapy.
    Ehrlich D; Ather N; Rahal H; Donahue TR; Hines OJ; Kim S; Sedarat A; Muthusamy VR; Watson R
    J Gastrointest Surg; 2020 Dec; 24(12):2807-2813. PubMed ID: 31823316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant chemoradiotherapy for locally advanced pancreas cancer rarely leads to radiological evidence of tumour regression.
    Dudeja V; Greeno EW; Walker SP; Jensen EH
    HPB (Oxford); 2013 Sep; 15(9):661-7. PubMed ID: 23458352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Added value of CA19-9 response in predicting resectability of locally advanced pancreatic cancer following induction chemotherapy.
    van Veldhuisen E; Vogel JA; Klompmaker S; Busch OR; van Laarhoven HWM; van Lienden KP; Wilmink JW; Marsman HA; Besselink MG
    HPB (Oxford); 2018 Jul; 20(7):605-611. PubMed ID: 29475787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy and neoadjuvant stereotactic body radiotherapy.
    Mellon EA; Jin WH; Frakes JM; Centeno BA; Strom TJ; Springett GM; Malafa MP; Shridhar R; Hodul PJ; Hoffe SE
    Acta Oncol; 2017 Mar; 56(3):391-397. PubMed ID: 27885876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of margin-negative resection of pancreatic ductal adenocarcinoma following neoadjuvant therapy: Diagnostic performance of NCCN criteria for resection vs CT-determined resectability.
    Jang JK; Choi SJ; Byun JH; Kim JH; Lee SS; Kim HJ; Yoo C; Kim KP; Hong SM; Seo DW; Hwang DW; Kim SC
    J Hepatobiliary Pancreat Sci; 2022 Sep; 29(9):1025-1034. PubMed ID: 35658103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diffusion-weighted MRI predicts the histologic response for neoadjuvant therapy in patients with pancreatic cancer: a prospective study (DIFFERENT trial).
    Okada KI; Kawai M; Hirono S; Kojima F; Tanioka K; Terada M; Miyazawa M; Kitahata Y; Iwahashi Y; Ueno M; Hayami S; Murata SI; Shimokawa T; Yamaue H
    Langenbecks Arch Surg; 2020 Feb; 405(1):23-33. PubMed ID: 31993737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association Between Changes in Body Composition and Neoadjuvant Treatment for Pancreatic Cancer.
    Sandini M; Patino M; Ferrone CR; Alvarez-Pérez CA; Honselmann KC; Paiella S; Catania M; Riva L; Tedesco G; Casolino R; Auriemma A; Salandini MC; Carrara G; Cristel G; Damascelli A; Ippolito D; D'Onofrio M; Lillemoe KD; Bassi C; Braga M; Gianotti L; Sahani D; Fernández-Del Castillo C
    JAMA Surg; 2018 Sep; 153(9):809-815. PubMed ID: 29801062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant therapy for pancreatic cancer: Limitations and advances of response assessment (Review).
    Xu J; Zhan H; Li F; Hu S; Wang L
    Oncol Rep; 2021 Apr; 45(4):. PubMed ID: 33649823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of defining borderline resectable pancreatic cancer.
    Kang MJ; Jang JY; Kwon W; Kim SW
    Pancreatology; 2018 Mar; 18(2):139-145. PubMed ID: 29274720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative CT staging of borderline pancreatic cancer patients after neoadjuvant treatment: accuracy in the prediction of vascular invasion and resectability.
    Ahmed SA; Mourad AF; Hassan RA; Ibrahim MAE; Soliman A; Aboeleuon E; Elbadee OMA; Hetta HF; Jabir MA
    Abdom Radiol (NY); 2021 Jan; 46(1):280-289. PubMed ID: 32488556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of neoadjuvant combined chemotherapy and radiation therapy on the CT evaluation of resectability and staging in patients with pancreatic head cancer.
    Kim YE; Park MS; Hong HS; Kang CM; Choi JY; Lim JS; Lee WJ; Kim MJ; Kim KW
    Radiology; 2009 Mar; 250(3):758-65. PubMed ID: 19164113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.